ArticleBlood cancer journal2021
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.
Article in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 101 citations in OpenAlex.
- A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis.American journal of hematology · 2026Article
- Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010-2020.Bone marrow transplantation · 2026Article
- Real World Data and Its Impact on the Management of Plasma Cell Dyscrasias.Current hematologic malignancy reports · 2026Review
- Management of relapsed/refractory AL amyloidosis.Blood advances · 2026Review
- Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases.HemaSphere · 2026Article
- Case Report: Autologous stem cell transplantation in a patient diagnosed with AL amyloidosis in Kazakhstan.Frontiers in oncology · 2026Article
- Monoclonal gammopathy of renal significance from a hematologic perspective.Hematology. American Society of Hematology. Education Program · 2025Review
- Monoclonal-related neuropathies: diagnosis, prognosis, and outcomes.Hematology. American Society of Hematology. Education Program · 2025Review
- Amyloid Light Chain Proteins in Cardiovascular Disease: Pathogenesis and Emerging Therapies for Cardiac Amyloidosis.Pharmaceutical research · 2025Review
- Efficacy of venetoclax in the treatment of relapsed/refractory light-chain amyloidosis.Annals of hematology · 2025Article
- Article
- Concurrent TTR and AL Amyloidosis: Diagnostic Challenges and Clinical Implications.JACC. Case reports · 2025Article
- From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysis.Blood advances · 2025Article
- Timely Intervention in Light Chain Cardiac Amyloidosis.JACC. Case reports · 2025Article
- Recent developments in systemic light-chain amyloidosis prognosis and treatment.Future cardiology · 2025Review
- BCMA CAR-T: From Multiple Myeloma to Light-Chain Amyloidosis.Current oncology (Toronto, Ont.) · 2025Review
- The Impact of Melphalan Conditioning and CD34American journal of hematology · 2025Article
- The molecular landscape of AL amyloidosis.British journal of haematology · 2025Review
- Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias.Frontiers in immunology · 2025Review
- AL Amyloidosis: Current Treatment and Outcomes.Advances in hematology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 14 institutions in 4 countries.
Funding
Abstract
Venetoclax is efficacious in relapsed/refractory t(11;14) multiple myeloma, thus warranting investigation in light-chain amyloidosis (AL). This retrospective cohort includes 43 patients with previously treated AL, from 14 centers in the US and Europe. Thirty-one patients harbored t(11;14), 11 did not, and one t(11;14) status was unknown. Patients received a venetoclax-containing regimen for at least one 21- or 28-day cycle; the median prior treatments was three. The hematologic response rate for all patients was 68%; 63% achieved VGPR/CR. t(11;14) patients had higher hematologic response (81% vs. 40%) and higher VGPR/CR rate (78% vs. 30%, odds ratio: 0.12, 95% CI 0.02-0.62) than non-t(11;14) patients. For the unsegregated cohort, median progression-free survival (PFS) was 31.0 months and median OS was not reached (NR). For t(11;14), median PFS was NR and for non-t(11;14) median PFS was 6.7 months (HR: 0.14, 95% CI 0.04-0.53). Multivariate analysis incorporating age, sex, prior lines of therapy, and disease stage suggested a risk reduction for progression or death in t(11;14) patients. Median OS was NR for either subgroup. The organ response rate was 38%; most responders harbored t(11;14). Grade 3 or higher adverse events occurred in 19% with 7% due to infections. These promising results require confirmation in a randomized clinical trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.